Article Text

Download PDFPDF

86 Endometrial Cancer Immunohistochemical Risk Stratification in a large uterine-confined cancer series
  1. E Perrone1,
  2. F De Felice2,
  3. I Capasso1,
  4. D Arciuolo3,
  5. E Distefano1,
  6. D Lorusso1,
  7. GF Zannoni3,
  8. G Scambia1 and
  9. F Fanfani1
  1. 1Agostino Gemelli University Policlinic, UOC Ginecologia Oncologica, Dipartimento per la salute della Donna e del Bambino e della Salute Pubblica, Roma, Italy
  2. 2Policlinico Umberto I, Radiotherapy, Roma, Italy
  3. 3Agostino Gemelli University Policlinic, Gyneco-pathology and Breast Pathology Unit, Roma, Italy


Introduction/Background*Nowadays, after the recent insights about the molecular Endometrial cancer (EC) classification, the usual key histological parameters (i.e histotype and grade) have been shown to have poor reproducibility and adequacy in EC stratification risk. The need to define a more precise guidance of surgical and adjuvant approaches has suggested the possibility to refine the prognostic assessing, considering other EC characteristics. Inspired by these concepts, the aim of this study is to assess the clinical reproducibility and the oncological validity of the EC risk stratification based on the molecular information given by the immunohistochemistry (IHC).

Methodology Retrospective IHC analyses were conducted in a large series of 778 pre-operative uterine-confined ECs, studying the presence/absence of MLH1, MSH2, MSH6, to define the mismatch repair (MMR) stable or instable phenotype; the presence of p53 mutations and other molecular features. The molecular profile was correlated with histological, clinical and prognostic EC patients data.

Result(s)*Based on the IHC, we defined 3 EC populations: MMR stable (MMRs), instable (MMRi) and p53 mutated (p53+) patients. Our result demonstrated that the IHC stratification statistically correlated with the most relevant anatomo-clinical features: FIGO stage (p<0.001), grading (12,5% G3 in MMRs vs 22.9% in MMRi vs 95.3% in p53+, p<0.001), histotype (Type II 6.2% in MMRs vs 5.3% in MMRi vs 87.5% in p53+, p<0.001), presence of LVSI (positive in 16.3% in MMRs vs 23.8% in MMRi vs 38.7% in p53+, p<0.001), myometrial invasion and tumor dimension (p=0.003 and p<0.001 respectively). Again, the 3 IHC populations statistically reflected the EC risk class ESGO-ESMO-ESP classification 2020 (p<0.001) (table 1). These results were confirmed also in Kaplan-Meier curves in terms of over-all survival (OS) and disease-free survival (DFS) (p<0.0001) (figure 1). Moreover, the multivariate analyses demonstrated that absence of estrogen receptor (ER) impacted the OS (p=0.011) and, the Age>60 years and the ER-status in DFS (p=0.004 and p=0.041).

Abstract 86 Table 1

Distribution of clinicopathological parameters

Conclusion*In this large series, we demonstrated that the pragmatic and sistematic use of IHC may have an important role to properly stratify, in terms of histological features and clinical outcome, the pre-operative uterine-confined EC patients.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.